Search Within

Alexander Edward Drilon

  1. "Matteo Repetto"
Formats
  1. Meeting Abstract (5)
  2. Review (5)
  3. Journal Article (4)
  4. Editorial (1)
Groups
  1. Department of Medicine (15)
  2. Sloan Kettering Institute Postdocs (15)
  3. Solid Tumor Oncology Division (15)
  4. Thoracic Oncology (15)
  5. GME, Medicine (12)
  6. Graduate Medical Education (12)

More Groups

People
  1. Matteo Repetto (15)
  2. Mark Donoghue (5)
  3. Soo Ryum Yang (5)
  4. Allison Richards (4)
  5. Antoine Desilets (4)
  6. Pier Selenica (4)

More People

Years
  1. 2025 (1)
  2. 2024 (9)
  3. 2023 (5)
Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Oncology (1)
  3. British Journal of Cancer (1)
  4. Cancer (1)
  5. Cancer Discovery (1)
  6. Cancer Treatment Reviews (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Inc. (2)
  3. Adis International Ltd (1)
  4. American Association for Cancer Research (1)
  5. John Wiley & Sons (1)
  6. MDPI (1)

More Publishers

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Drilon, A.
    Cancer (2025)

    Fulltext@MSK | Save
  • Precision oncology: 2024 in review
    Review

    Repetto, M.; Fernandez, N.; Drilon, A.; Chakravarty, D.
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer
    Editorial

    Desilets, A.; Repetto, M.; Drilon, A.
    Clinical and Translational Medicine (2024)

    Fulltext@MSK | Save
  • RET inhibitors in RET fusion-positive lung cancers: Past, present, and future
    Review

    Chen, M. F.; Repetto, M.; Wilhelm, C.; Drilon, A.
    Drugs (2024)

    Fulltext@MSK | Save
  • Diverging acquired resistance evolutionary pathways in fusion-positive patients treated with tyrosine kinase inhibitors
    Meeting Abstract

    Repetto, M.; Selenica, P.; Gazzo, A.; Richards, A. L.; Reis-Filho, J. S.; Jee, J.; Donoghue, M.; Weigelt, B.; Drilon, A. E.; Choudhury, N. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types
    Meeting Abstract

    Gormally, M.; Repetto, M.; Jee, J.; Chang, J. C.; Selenica, P.; Gazzo, A.; Richards, A. L.; Donoghue, M.; Aghajanian, C.; Reis-Filho, J. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort
    Meeting Abstract

    Desilets, A.; Repetto, M.; Kemel, Y.; Khurram, A.; Mandelker, D.; Bandlamudi, C.; Novak, B.; Velilla, C.; Selenica, P.; Richards, A. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
    Journal Article

    Roa, P.; Foglizzo, V.; Harada, G.; Repetto, M.; Kulick, A.; de Stanchina, E.; de Marchena, M.; Auwardt, S.; Sayed Ahmed, S.; Bremer, N. V.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
    Journal Article

    Thawani, R.; Repetto, M.; Keddy, C.; Nicholson, K.; Jones, K.; Nusser, K.; Beach, C. Z.; Harada, G.; Drilon, A.; Davare, M. A.
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • NTRK gene fusion testing and management in lung cancer
    Review

    Repetto, M.; Chiara Garassino, M.; Loong, H. H.; Lopez-Rios, F.; Mok, T.; Peters, S.; Planchard, D.; Popat, S.; Rudzinski, E. R.; Drilon, A.; more...
    Cancer Treatment Reviews (2024)

    Fulltext@MSK | Save